Notizie/Reuters/Cingulate Submits New Drug Application To FDA For Lead Adhd Asset CTx-1301Cingulate Submits New Drug Application To FDA For Lead Adhd Asset CTx-1301RefinitivMeno di 1 minuto di letturaCINGCingulate Inc CING:CINGULATE SUBMITS NEW DRUG APPLICATION TO FDA FOR LEAD ADHD ASSET CTX-1301Azioni USAReuters© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.htmlMostra di piùAccedi o crea un account gratuito per leggere queste notizieAndiamo
